Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
FDA expands label for AZ's Tagrisso in NSCLC indication
The FDA has signed off on Tagrisso to become the first targeted therapy for unresectable, stage 3 EGFRm non-small cell lung cancer.
Kevin Dunleavy
Sep 26, 2024 10:52am
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
Sep 20, 2024 11:00am
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Sep 8, 2024 11:30am
Merck’s Keytruda flunks pivotal studies in lung and skin cancers
Aug 29, 2024 10:16am
